BCSC alleges fraud and illegal distribution against two B.C. residents and purported pharmaceutical company (ENGLISH and CHINESE)
Vancouver – The Executive Director of the British Columbia Securities Commission (BCSC) has issued a notice of hearing against Winter Huang (a.k.a. Dong Huang), Vicky Dancho (a.k.a. Ju Huang) and two B.C. incorporated companies alleging that they perpetrated fraud and distributed securities illegally.
The notice states that Huang was a B.C. resident and a director and controlling mind of Pegasus Pharmaceuticals Group Inc. and Careseng Cancer Institute Inc. Dancho is Huang’s sister and resides in Richmond, B.C. Dancho was a director, the CEO, and the President of Careseng Cancer. None of the respondents have ever been registered in B.C. under any capacity.
BCSC staff alleges that between April 2008 and August 2012, Pegasus Pharmaceuticals raised approximately USD$65 million by issuing approximately 1,800 Pegasus Pharmaceuticals bonds in 11 series to investors in Taiwan, purportedly for different business projects under its control. Each bond consisted of an investment certificate and a promissory note. Huang signed the investment certificate and promissory note as Chairman and President of Pegasus Pharmaceuticals. Approximately 800 of the 1,800 promissory notes stated that Careseng Cancer guaranteed repayment of principal at maturity. Dancho signed these promissory notes as a director of the guarantor, Careseng Cancer. Staff maintains that approximately USD$56 million of these distributions breached securities laws concerning prospectus and registration requirements.
Huang is further alleged to have committed fraud by signing promissory notes, guaranteed by Careseng Cancer, on behalf of Pegasus Pharmaceuticals. Dancho is alleged to have committed fraud by signing promissory notes totaling approximately $36.4 million on behalf of Careseng Cancer. Staff contends that Huang and Dancho knew, or ought to have known, that these guarantees were false as Careseng Cancer had no operations, no employees, no revenue, and less than USD $50,000 in assets.
Staff also alleges that between January 2011 and August 2012, Pegasus Pharmaceuticals fraudulently raised approximately USD$15.4 million by selling bonds purportedly for projects in the Republic of Georgia, and USD$11.1 million by selling bonds purportedly related to a project in Dalian, China. Staff contends that only approximately USD $1.4 million was put towards the Georgian projects, and only approximately USD $560,000 was put towards the Dalian project. Instead, Pegasus Pharmaceuticals used the remaining investor funds to make payments to earlier investors, pay commissions to Pegasus Pharmaceuticals bonds sales agents, and for Pegasus Pharmaceuticals’ operational costs unrelated to the projects. As director and controlling mind of Pegasus Pharmaceuticals, Huang is also alleged to have perpetrated fraud against investors.
The BCSC urges anyone who has invested with Pegasus Pharmaceuticals Group Inc., or has information about it or any of its associated companies, to contact the BCSC by email at email@example.com.
BCSC staff acknowledges and appreciates the assistance provided by the Securities and Futures Bureau of Taiwan and the Securities and Futures Commission of Hong Kong during this investigation.
These allegations have not been proven. Counsel for the Executive Director will apply to set dates for a hearing into the allegations before a panel of commissioners on February 23, 2016 at 9:00am.
You may view the notice of hearing on our website www.bcsc.bc.ca by typing Pegasus Pharmaceuticals Group Inc., Careseng Cancer Institute Inc., Winter Huang (Dong Huang), Vicky Dancho (Ju Huang) or 2016 BCSECCOM 25 in the search box. Information regarding disciplinary proceedings can be found in the Enforcement section of the BCSC website.
Please visit the Canadian Securities Administrators’ Disciplined Persons List for information relating to persons disciplined by provincial securities regulators, the Investment Industry Regulatory Organization of Canada (IIROC) and the Mutual Fund Dealers Association (MFDA).
About the British Columbia Securities Commission (www.bcsc.bc.ca)
The British Columbia Securities Commission is the independent provincial government agency responsible for regulating capital markets in British Columbia through the administration of the Securities Act. Our mission is to protect and promote the public interest by fostering:
- A securities market that is fair and warrants public confidence
- A dynamic and competitive securities industry that provides investment opportunities and access to capital
- 30 -
Richard Gilhooley, Media Relations
604-899-6854 or 1-800-373-6393 (toll free)
Learn how to protect yourself and become a more informed investor at www.investright.org
温哥華-卑斯證監會(BCSC)執行總監發出了聆訊通告給Winter Huang (又名黄冬), Vicky Dancho (又名Ju Huang)及兩間卑斯省注冊的公司，指他們欺詐及非法發行證券。
卑斯證監會人員指在2008 年4月至2012 年8月期間，天馬藥業發行了11個系列約1,800份天馬藥業債券給台灣的投資者，並聲稱會用於其控制下的不同的商業項目，籌得約六千五百萬美元。每份債券包括一張投資證書及一張期票。黃以天馬藥業董事長兼總裁的身分在投資證書及期票上簽名。 1,800張期票中的約800 張聲稱科爾興腫瘤保證到期歸還本金。Dancho以擔保機構科爾興腫瘤董事的身分在這些期票上簽名。證監會人員認為其中發行的約五千六百萬美元違反證券法有關公開說明書及註冊的規定。
卑斯證監會人員又指在2011 年1月至2012 年8月期間，天馬藥業以欺詐手段售賣聲稱會用於格魯吉亞共和國項目的債券而籌得約一千五百四十萬美元及售賣聲稱與中國大連一個項目有關的債券而籌得約一千一百一十萬美元。卑斯證監會人員認為只有約一百四十萬美元用於格魯吉亞項目及只有約五十六萬美元用於大連項目。天馬藥業反而用其餘的投資者資金來支付早期的投資者，支付佣金給替天馬药業售賣債券的銷售代理及與項目無關的天馬药業營運開支。作為天馬药業的董事及主腦，黄亦被指欺詐投資者。
這些聲稱還未經證實。代表證監會執行總監的律師將於2016 年2月23日上午9 時向專員小組申請排期聆訊。
公眾可以到我們網址www.bcsc.bc.ca在搜索欄輸入天馬藥業集團公司, 科爾興腫瘤防治網絡公司，Winter Huang (Dong Huang)，Vicky Dancho (Ju Huang) 或2016BCSCECCOM 25閱覽聆訊通告。有關制裁訴訟的資料可於卑斯證監會網址執行部門中找到。
請於加拿大證券管理人(the Canadian Securities Administrators) 受制裁人士名單中閱覽受到省證監會，加拿大投資行業監管組織(IIROC)及互惠基金交易員協會
Richard Gilhooley, 傳媒關係
604-899-6854 or 1-800-373-6393 (免費)